Safety Considerations and Side Effect Management with Tyverb (Lapatinib)
|
|
- Andrew James
- 5 years ago
- Views:
Transcription
1 Safety Considerations and Side Effect Management with Tyverb (Lapatinib) Prescribing information can be found at the end of the presentation Date of prep: 19-Sep-2011 UK/LPD/0226a/11
2 HER2 (ErbB2)-positive Breast Cancer Breast Cancer is the most common malignancy in women in UK - Approximately 48,000 new cases and 12,000 deaths in UK in Approximately 15-30% of patients have tumours that overexpress HER2 2,3 HER2-postive disease tends to be more aggressive, less responsive to chemotherapy and has a poorer prognosis Average survival time, with treatment, from diagnosis of advanced or metastatic disease is months; reduced by up to 50% if HER Cancer Research UK. UK breast cancer incidence and mortality statistics. Accessed: 20/05/ Penault-Llorca et al. JCO NICE. Technology Appraisal Guidance No. 34. London: NICE, 2002.
3 Introduction Small molecule, works intracellularly Targets both the EGFR (ErbB1) and HER2 (ErbB2) receptors Once-daily oral treatment Treatment option for HER2 patients with metastatic disease - in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes, and therapy with trastuzumab in the metastatic setting - in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor Tyverb Summary of Product Characteristics May 2011
4 Practical Considerations: Lapatinib/Capecitabine Combination Practical Considerations Lapatinib Capecitabine Dosage/administration 1250mg ONCE daily 1000mg/m 2 TWICE daily Food interaction Taken continuously 250mg tablets (5 tablets/day) > 1 hour pre- or post food (standardised) 14 day cycle with 7 day rest 150mg/ 500mg tablets (3-7 tablets twice daily) Within 30 minutes after food Do not crush, take whole one at a time with a glass of water Grapefruit juice Drug interaction Avoid concomitant treatment with inducers or inhibitors of CYP3A4 Refer to SmPC for further details Please refer to Tyverb and Xeloda Summary of Product Characteristics for full details
5 Practical Considerations: Lapatinib/Aromatase Inhibitor Combination Practical Considerations Lapatinib Aromatase Inhibitor Dosage/administration 1500mg ONCE daily ONCE daily Food interaction 250mg tablets (6 tablets/day) > 1 hour pre- or post food (standardised) Do not crush, take whole one at a time with a glass of water Grapefruit juice Taken continuously Letrozole: 2.5mg (1 tablet/day) Anastrozole: 1mg (1 tablet/day) Exemestane: 25mg (1 tablet/day) Refer to respective SmPC for full details Drug interaction Avoid concomitant treatment with inducers or inhibitors of CYP3A4 Please refer to the Summaries of Product Characteristics for full details
6 Introduction to the Guiding your patient through Tyverb treatment material
7
8
9
10 Tyverb Information for patients and healthcare professionals Practical advice on administration/dosage
11 Questions your patient may ask... What should I do if I forget to take my Tyverb? Answers: - If it is still the same day, take your Tyverb tablets as soon as you remember. Do NOT double the dose the next day - Remember to inform the cancer unit What if I missed a whole day? Answers: - Take the usual dose of Tyverb on the day after the missed day at the usual time(s) - Remember to inform the cancer unit
12 Questions your patient may ask... What if I am sick after taking Tyverb? Answers: - Do not take a second dose to make up for the vomited dose - Take the next dose as normal when due - If vomiting continues, contact the cancer unit Can I crush, split or dissolve the tablets? Answers: - Tyverb tablets should be swallowed whole with a drink of water - Crushing, splitting, chewing and dissolving the tablets are not recommended - Talk to the breast cancer/chemotherapy nurse if experiencing difficulty taking tablets
13 Management of Tyverb-associated side effects
14 Common Side Effects Safety of Tyverb evaluated as monotherapy or in combination with other chemotherapies for various cancers in more than 11,000 patients including: patients who received Tyverb in combination with capecitabine (EGF100151) patients who received Tyverb in combination with letrozole (EGF30008) Most common AEs (>25%) during therapy with Tyverb were gastrointestinal events (such as diarrhoea, nausea, and vomiting) and rash. Tyverb Summary of Product Characteristics May 2011
15 EGF most common adverse events (all grades) Cameron D, et al. Breast Can Res Treat 2008;112:
16 EGF most common adverse events (all grades) Diarrhoea Johnston S et al. J Clin Oncol ;
17
18 Management of Diarrhoea associated with Tyverb
19 Diarrhoea events across several Tyverb studies The incidence and characteristics of diarrhoea associated with Tyverb treatment have been reviewed across several clinical trials Grade Diarrhoea events were mainly grade 1 and grade 2 (mild to moderate) Grade 3 and 4 events occurred in 9% and <1% of patients, respectively Onset and duration 42% of patients who experienced diarrhoea developed it within the first 6 days of treatment Each episode lasted a median of 5 days Few patients had events worsen from grade 1 or 2 Management and resolution Vast majority (92%) of diarrhoea events resolved. Most (85%) events required no interruption, dose adjustment or discontinuation of treatment Diarrhoea infrequently led to withdrawal of Tyverb (2%) Patients who required intervention responded to standard anti-diarrhoeal medications (e.g. loperamide). In more severe cases, management included hydration and use of antibiotics Crown JP et al. Breast Cancer Res Treat 2008
20
21 5 steps for managing diarrhoea 1. TELL SOMEONE 2. DRINK PLENTY OF CLEAR FLUIDS 3. LOPERAMIDE
22
23
24 5 steps for managing diarrhoea 1. TELL SOMEONE 2. DRINK PLENTY OF CLEAR FLUIDS 3. LOPERAMIDE 4. EAT THE RIGHT THINGS
25
26
27 5 steps for managing diarrhoea 1. TELL SOMEONE 2. DRINK PLENTY OF CLEAR FLUIDS 3. LOPERAMIDE 4. EAT THE RIGHT THINGS 5. ASSESS YOUR DIARRHOEA
28 Questions your patient may ask What should I do if I get diarrhoea whilst taking Tyverb? Answers: If diarrhoea occurs it usually happens during the first week or so but can happen at any time during treatment It is usually mild or moderate, but can be severe in some cases Most people with diarrhoea should be able to continue their treatment with Tyverb with appropriate management If experiencing diarrhoea or a change in your normal bowel pattern, inform the cancer unit
29 Management of Skin Rash associated with Tyverb
30 Pooled analysis of skin events associated with Tyverb... Among Tyverb-treated patients across nine clinical trials (n= 1417): Skin events were reported in 70% with Tyverb + capecitabine The majority of events were of low-grade severity (Grade 1 or 2) No Grade 4 events Events tend to present early in the course of treatment Days 1 14 are usually self-limiting (median duration 29 days) Presentation of rash is variable Dermatitis is the predominant event Pruritus / urticaria (3%), hair disorder (3%) and nail disorders/infection (< 1%) are infrequent Distribution of events is mostly on the trunk ; however facial rash may occur Majority (88%) did not require Tyverb dose adjustment or treatment interruption 1% discontinued therapy Lacouture ME et al. Breast Cancer Res Treat 2008
31 Examples of skin events associated with Tyverb Grade 1 Grade 3 Grade 2 Lacouture ME et al. Breast Cancer Res Treat 2008
32 Management of rash... There are no clear evidence-based treatment options for skin rashes or other skin reactions associated with Tyverb 1 Mild to moderate skin events are most often seen in first 14 days of Tyverb treatment, usually self-limiting, lasting on average 29 days 2 The most commonly seen rash is a acneiform rash on the upper body, which may include the face and/or scalp 2 Patients should receive a skin examination prior to starting Tyverb treatment and at regular intervals thereafter 1. Moy B & Goss PE. The Oncologist Lacouture ME et al. Breast Cancer Res Treat 2008
33 Management of rash Patients experiencing skin events should: - Avoid sunlight - Apply a suncream (SPF 30) - Have full body examinations until one month after resolution Interruption of Tyverb treatment should be considered for skin events with associated pruritus, desquamation or vesicular eruption in addition to macular/papular eruption or erythema Pharmacological intervention is at the clinician s discretion (e.g., oral or topical antibiotics, topical corticosteroids) In severe cases, referral to a dermatologist is recommended Moy B & Goss PE. The Oncologist 2007
34
35 Questions your patient may ask What should I do if I get a rash while taking Tyverb? Answers: Rash is a very common side-effect of taking Tyverb It usually develops within the first 2 weeks of treatment The rash will usually improve or disappear after a few weeks Most people who develop a rash are able to continue their treatment with Tyverb If a rash develops, or if your skin feels dry, itchy or painful, inform your doctor or nurse
36 Tyverb cardiac side-effect profile
37 Decreased Left Ventricular Ejection Fraction (LVEF)... Across all clinical studies, LVEF decreases have been reported in approximately 1% of patients receiving Tyverb and were asymptomatic in more than 90% of cases Symptomatic LVEF decreases have been observed in approximately 0.2% of patients who received Tyverb as monotherapy or in combination with other anti-cancer agents Observed symptoms have included dyspnoea, cardiac failure and palpitations. Overall 58% of symptomatic subjects recovered Tyverb Summary of Product Characteristics May 2011
38 Decreased LVEF In the pivotal trial of Tyverb in combination with capecitabine versus capecitabine alone, LVEF decreases were reported in 2.5% of patients who received Tyverb in combination with capecitabine, compared to 1.0% with capecitabine alone In the pivotal trial of Tyverb in combination with letrozole versus letrozole alone, LVEF decreases were reported in 3.1% of patients in the Tyverb plus letrozole group, compared to 1.3% in patients receiving letrozole alone Tyverb Summary of Product Characteristics May 2011
39 LVEF monitoring LVEF should be assessed by an echocardiogram (ECHO) or multigated acquistion (MUGA) scan in all patients before starting Tyverb treatment to check that their baseline LVEF is within institutional limits of normal 1 LVEF should also be monitored during treatment to ensure that it does not fall to an unacceptable level 1 Subsequent cardiac examinations should be performed using the same method as the baseline examination There is no specific recommendation as to how frequently LVEF should be assessed, but every few months would seem prudent 2 1. Tyverb Summary of Product Characteristics May Moy B & Goss PE. The Oncologist 2007
40 Recommendations for management of decreased LVEF Interrupt Tyverb if symptoms associated with decreased LVEF are NCI CTCAE > Grade 3 and/or if LVEF drops below LLN Restart Tyverb at a reduced dose (1000mg/day) after > 2 weeks if LVEF recovers to normal and symptoms resolve Monitor LVEF regularly after re-challenge If symptoms recur, discontinue treatment permanently LLN = Institution s Lower Limit of Normal Tyverb Summary of Product Characteristics May 2011
41 Hepatobiliary Events
42 Hepatobiliary events associated with Tyverb treatment Hepatobiliary events are a recognised class effect of tyrosine kinase inhibitors e.g. erlotinib, imatinib 1,2 Adverse liver events also reported with capecitabine treatment 3 Hepatobiliary events have been observed during Tyverb treatment 4 Mainly elevated liver enzymes and/or bilirubin levels Commonly reported with Tyverb plus capecitabine ( 1/100 to < 1/10) 4 Generally returned to normal on stopping treatment 1. Tarceva Summary of Product Characteristics; 2. Glivec Summary of Product Characteristics; 3. Xeloda Summary of Product Characteristics; 4. Tyverb Summary of Product Characteristics May 2011
43 Management of hepatobiliary events associated with Tyverb Liver function should be monitored AST/ALT, alkaline phosphatase, bilirubin Before initiation of treatment Monthly thereafter, or as clinically indicated Discontinue Tyverb if changes in liver function are severe and do not re-treat Use Tyverb with caution in patients with moderate or severe hepatic impairment Insufficient data to provide a dose adjustment recommendation Tyverb Summary of Product Characteristics May 2011
44 Other useful information in A step-by-step guide to your treatment 8 week treatment guide pg 24 Fridge magnet and food lists pg 34 Recipe cards/shopping lists pg 40
45 Summary Lapatinib, an oral targeted therapy, in combination with: - capecitabine or - an aromatase inhibitor has a predictable and manageable side effect profile Diarrhoea and rash are amongst the most frequent adverse events Prompt diagnosis and management of side effects is important Patient education plays a major role in the prevention and early detection of side effects To have clear guidelines in place is critical
46 46
47 Additional slides
48 Diarrhoea Associated with Lapatinib Treatment Management Guidelines EVALUATION Obtain history of onset and duration of diarrhoea Describe number of stool as composition (e.g. watery, contain blood) Assess for fever, dizziness, abdominal cramping to rule out risk for sepsis, bowel obstruction and dehydration Dietary profile Uncomplicated grade 1-2, MANAGEMENT Dietary modifications (stop all lactose-containing products; eat small meals) Hydration (drink 8-10 large glasses of clear liquids [Gatorade, broth] per day For grade 2 diarrhoea: Consider withholding lapatinib and other cytotoxic treatment Consider lapatinib dose reduction TREATMENT Administer standard loperamide dosing (especially in high-risk patients) 4 mg initially, then 2 mg every 4 h or after every unformed stool Re-assess 24 hrs later Symptoms persist Complicated grade 3-4 or grade 1-2 with complicating features (cramping, nausea/ vomiting grade 2, decreased performance status, fever, sepsis, neutropenia, frank bleeding and/or dehydration) MANAGEMENT Hospitalisation for patients at risk for life-threatening complications (i.e. with GI syndrome) Patient must call physician immediately for any complicated, severe diarrhoea event Discontinue lapatinib and other cytotoxic treatment Hydration (intravenous fluids as needed); for severe dehydration administer octreotide TREATMENT Initiate loperamide immediately 4 mg initially, then 2 mg every 2 h or after every unformed stool Administer antibiotics as needed (especially if there is fever or grade 3-4 neutropenia or symptoms persist >24 hrs) DIARRHOEA RESOLVING Continue instruction for dietary modification Gradually add solid foods to diet Discontinue loperamide treatment after 12-hr diarrhoea-free interval DIARRHOEA UNRESOLVED Administer loperamide 2 mg every 2 hrs plus oral antibiotics Re-assess 24 hrs later DIARRHOEA UNRESOLVED Start second-line agents* (octreotide, budesonide or tincture of opium) DIARRHOEA-FREE FOR 24 HRS Discontinue intervention Consider re-introducing lapatinib (and other cytotoxic therapy) at reduced dose) Guidelines developed by GSK based on Benson et al. J Clin Oncol 2004; 22: *unlicensed agents for this indication
49 NCI CTC grading: Rash Grade Rash 1 Macular or papular eruption or erythema without associated symptoms 2 Macular or papular eruption or erythema + itching / other associated symptoms. Local desquamation. Covering <50% BSA 3 Severe. Confluent lesions, or vesicular eruption; desquamation covering >50% BSA 4 Generalised rash, deep ulcerations, exfoliative or bullous dermatitis 5 Death National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0,
Lapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationLapatinib (Tyverb ) plus Capecitabine (Xeloda ) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Days 1 to 21 Days 1 to 14 Lapatinib Capecitabine 1250mg ONCE a day 1000 mg/m 2 twice a day* Oral N/A Continuous BO22-Laptinib-Capecitabine-protocol-CRP10-v1.3
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationERLOTINIB (TARCEVA ) FOR NSCLC
DRUG ADMINISTRATION SCHEDULE Day Cycle length Drug Daily Dose Route Schedule Days 1 to 28 Continuous Erlotinib 150 mg Oral ONCE daily DOSE FORM Presented as 25mg, 100mg and 150mg Tablets CYCLE LENGTH AND
More informationLung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA258 NICE TA162 Locally advanced or metastatic NSCLC as a first line treatment option Positive test for epidermal growth
More informationPaclitaxel and Trastuzumab Breast Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel and Trastuzumab Breast Cancer PROTOCOL REF: MPHAPTRBR (Version No: 1.0) Approved for use in: HER2 positive breast cancer. For adjuvant use in T1 or T2
More informationLapatinib and capecitabine for breast cancer Funding arrangements to be set up and specified locally Page 1 of 5
Indication: Funding arrangements to be set up and specified locally Page 1 of 5 Lapatinib in combination with Capecitabine is recommended as a treatment option for people with advanced and/or metastatic
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29
Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive
More informationNCCP Chemotherapy Regimen. Afatinib Therapy
INDICATIONS FOR USE: Afatinib Therapy Regimen Code INDICATION ICD10 Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationCapecitabine plus Docetaxel in Advanced Breast Cancer
Capecitabine plus Docetaxel in Advanced Breast Cancer Indication: Palliative therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer Regimen details: Docetaxel 75mg/m 2 IV D1 Capecitabine*
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationOsimertinib Early Access Scheme
Systemic Anti Cancer Treatment Protocol Osimertinib Early Access Scheme PROTOCOL REF: MPHALUNOSI (Version No: 1.0) Approved for use in: In EGFR T970M mutation positive NSCLC who have progressed on or after
More informationCAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1)
West of Scotland Cancer Network Chemotherapy Protocol Indication CAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1) Capecitabine (Xeloda) monotherapy is indicated for the treatment of locally advanced
More informationPertuzumab, Herceptin (Trastuzumab) and Docetaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Cycle One Loading Doses Day 1 Paracetamol 1g Oral Day 1 Ondansetron 8mg Oral /Slow bolus/15 min infusion Day 1 Pertuzumab 840mg IV Infusion Pertuzumab and Herceptin can be
More informationNCCP Chemotherapy Protocol. Afatinib Monotherapy
Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationNECN Chemotherapy Handbook Protocol
DRUG ADMINISTRATION SCHEDULE Day Cycle length Drug Daily Dose Route Schedule Days 1 to 28 Continuous Erlotinib 150 mg Oral ONCE daily DOSE FORM Presented as 25mg, 100mg and 150mg Tablets CYCLE LENGTH AND
More informationAUSTRALIAN PRODUCT INFORMATION - TYKERB (lapatinib) 250 mg tablets
AUSTRALIAN PRODUCT INFORMATION - TYKERB (lapatinib) 250 mg tablets 1. NAME OF THE MEDICINE Lapatinib (as ditosilate monohydrate) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance Each TYKERB
More informationBRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN) and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour Group: Contact
More informationErlotinib Non-Small Cell Lung Cancer
Systemic Anti Cancer Treatment Protocol Erlotinib Non-Small Cell Lung Cancer PROTOCOL REF: MPHAERLLU (Version No: 1.0) Approved for use in: First line treatment of locally advanced or metastatic epidermal
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationNCCP Chemotherapy Protocol. Erlotinib Monotherapy
Erlotinib Monotherapy INDICATIONS FOR USE: INDICATION First-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations. Switch maintenance
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:
More informationBreast Pathway Group Everolimus in Advanced Breast Cancer
Breast Pathway Group Everolimus in Advanced Breast Cancer Indication: Hormone receptor positive, HER2 negative advanced breast cancer National Cancer Drug Fund criteria: ER+ve, HER2 ve metastatic breast
More informationNerlynx (neratinib) NEW PRODUCT SLIDESHOW
Nerlynx (neratinib) NEW PRODUCT SLIDESHOW Introduction Brand name: Nerlynx Generic name: Neratinib Pharmacological class: Kinase inhibitor Strength and Formulation: 40mg; tabs Manufacturer: Puma Biotechnology
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine Protocol Code Tumour Group Contact Physician UBRAVTCAP Breast Dr. Stephen Chia ELIGIBILITY:
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationHerceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX)
Herceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX) DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent and Rate 1 to 21 Capecitabine 625mg/m 2 Day 1 TWICE DAILY Oral
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationIrinotecan Capecitabine (14 day regimen) (I-Cap)
Systemic Anti Cancer Treatment Protocol Irinotecan (14 day regimen) (I-Cap) PROTOCOL REF: MPHAICAP (Version No: 1.0) Approved for use in: Advanced colorectal cancer first line Advanced colorectal cancer
More informationCetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer
Cetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate
More informationJINARC (tolvaptan) Patient/carer education brochure
JINARC (tolvaptan) Patient/carer education brochure This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side
More informationAbemaciclib (Verzenios ) Abemaciclib (Verzenios )
Abemaciclib (Verzenios ) Abemaciclib (Verzenios ) Abemaciclib is a targeted (biological) therapy. This group of drugs block the growth and spread of cancer. They target and interfere with processes in
More informationNCCP Chemotherapy Regimen. Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day cycle
Pertuzumab and Therapy - 21 day cycle INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationCapecitabine Oxaliplatin 21 day cycle (CAPOX)
Systemic Anti Cancer Treatment Protocol Oxaliplatin 21 day cycle (CAPOX) PROTOCOL REF: MPHACAPOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage 2 Advanced
More informationTYKERB PRODUCT INFORMATION (Lapatinib Ditosylate) 250 mg tablets
TYKERB PRODUCT INFORMATION (Lapatinib Ditosylate) 250 mg tablets NAME OF THE DRUG TYKERB film-coated tablets contain lapatinib ditosylate which is a member of 4- anilinoquinazoline class of kinase inhibitors.
More informationPazopanib in Renal cell carcinoma
REGIMEN TITLE: Pazopanib in Renal cell carcinoma Page 1 of 5 Indication: Notes: First line treatment option in advanced renal cell carcinoma Patients who have not received prior cytokine therapy Eastern
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Protocol Code Tumour Group Contact Physician USMAVDT Skin and Melanoma Dr.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tyverb 250 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains lapatinib ditosylate
More informationHCX Herceptin, Cisplatin and Capecitabine
DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent Rate Sodium Chloride 0.9% 250 ml Infusion Fast Running Day 1 Furosemide 20mg IV bolus Via saline drip Trastuzumab 8mg/kg
More informationLung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel
More informationFEC-TPH (Fluorouracil, Epirubicin and Cyclophosphamide) followed by Docetaxel, Pertuzumab and Trastuzumab (Herceptin )
FEC-TPH (Fluorouracil, Epirubicin and Cyclophosphamide) followed by Docetaxel, Pertuzumab and Trastuzumab (Herceptin ) Indication Neo-adjuvant treatment for HER2 positive, locally advanced, inflammatory
More informationNCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel
More informationNCCP Chemotherapy Regimen. Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day
INDICATIONS FOR USE: Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day Regimen INDICATION ICD10 Code Locally advanced or metastatic gastric carcinoma C16 00239a Locally advanced or metastatic oesophageal
More informationErlotinib (Tarceva )
Erlotinib (Tarceva ) Erlotinib (Tarceva ) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer
More informationDocetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer
Docetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer Indication: Neoadjuvant therapy f HER 2 negative high risk and fit Breast Cancer patients, suitable f a taxane containing
More informationFor the Patient: CAP. Capecitabine. Uses:
For the Patient: CAP Other names: BRAVCAP CAP Capecitabine Uses: BRAVCAP is an oral chemotherapy drug treatment plan, given as therapy for metastatic breast cancer, in the hope of destroying breast cancer
More informationVerzenio (abemaciclib) NEW PRODUCT SLIDESHOW
Verzenio (abemaciclib) NEW PRODUCT SLIDESHOW Introduction Brand name: Verzenio Generic name: Abemaciclib Pharmacological class: Kinase inhibitor Strength and Formulation: 50mg, 100mg, 150mg, 200mg; tabs
More informationGemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
More informationWest of Scotland Cancer Network Chemotherapy Protocol
West of Scotland Cancer Network Chemotherapy Protocol DOCETAXEL/TRASTUZUMAB (BRWOS-005/1) Indication Docetaxel in combination with is indicated for the treatment of patients with HER2 overexpressing locally
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationWARNING LETTER. According to the INDICATIONS AND USAGE section of the FDA-approved product labeling (PI)' for Tykerb:
EPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Chief Executive Officer GlaxoSmithKline P.O. Box 13398 Five Moore
More informationNCCP Chemotherapy Regimen
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationVinorelbine (Navelbine ) plus Capecitabine (Xeloda ) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Vinorelbine 60 to 80 mg/m 2 Oral N/A Stat Dose Days 1 to 14 Capecitabine 1000 mg/m 2 twice a day* Vinorelbine Capecitabine protocolcrp11b0024
More informationOpen to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level
If you have multiple myeloma and have already tried at least 2 other types of treatment Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level What is
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Capecitabine Monotherapy Regimen *Reimbursement INDICATION ICD10 Code Indicator Treatment of patients with locally advanced or metastatic breast cancer C50 00216a CDS Treatment of
More informationYONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE
YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE INDICATION YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received
More informationWhat is Abemaciclib (ABEM-a-si-clib) and how does it work?
PATIENT EDUCATION patienteducation.osumc.edu What is (ABEM-a-si-clib) and how does it work? is a type of oral, targeted cancer therapy called a cyclin D kinase inhibitor. Another name for this medicine
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationFEC-D with HP Fluorouracil, Epirubicin, Cyclophosphamide, Followed by Docetaxel, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Approved for use in: Neoadjuvant breast cancer: The neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early breast cancer at high risk of recurrence Interim CDF funding from November
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationCapecitabine and Lapatinib
PATIENT EDUCATION patienteducation.osumc.edu What is Capecitabine (ka-pe-site-a-been) and how does it work? Capecitabine is an oral chemotherapy drug known as an antimetabolite. Another name for this drug
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationLearning More Can Make a Difference
When your advanced or metastatic HER2+ breast cancer progresses on an anthracycline, a taxane, and Herceptin (trastuzumab) T U R N T O T Y K E R B + C A P E C I T A B I N E Learning More Can Make a Difference
More informationALUNBRIG (brigatinib) Dosing Guide
ALUNBRIG (brigatinib) Dosing Guide INDICATION ALUNBRIG (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationAnnex III. Amendments to relevant sections of the summary of product characteristics and package leaflets
Product Information as approved by the CMDh on 19 March 2014, pending endorsement by the European Commission Annex III Amendments to relevant sections of the summary of product characteristics and package
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationBCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine
BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAVCAP Breast Dr. Susan Ellard ELIGIBILITY: First line treatment of metastatic
More informationEGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide
EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide The information in this pocket guide is intended as reference material and should not replace clinical judgment or updated
More informationFEC-T plus trastuzumab & pertuzumab
Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer
More informationTrastuzumab emtansine Kadcyla
Trastuzumab emtansine Kadcyla Indication Treatment of HER2 positive unresectable locally advanced or metastatic breast cancer for patients who have previously received a taxane and trastuzumab (Herceptin
More informationYour Guide To Treatment With IBRANCE (palbociclib)
Your Guide To Treatment With IBRANCE (palbociclib) Patient s name: Oncologist s name: Oncologist s contact details: Your treatment: Ibrance with aromatase inhibitor (e.g. letrozole, anastrozole) with fulvestrant
More informationEC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer
EC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen EC
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationDabrafenib (Tafinlar )
Dabrafenib (Tafinlar ) Dabrafenib (Tafinlar ) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary. This treatment aims to control the cancer and its symptoms.
More informationHerceptin SC (Subcutaneous Trastuzumab)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Rate 1 Herceptin SC (trastuzumab) 600mg S/C 2 to 5 mins *PRECAUTION: In order to reduce the risk of medication errors it is recommended that all trastuzumab
More informationBCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using
BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or
More informationMethotrexate Methotrexate.indd 1 9/1/16 11:40 AM
Methotrexate 110465 Methotrexate.indd 1 9/1/16 11:40 AM This leaflet only provides information for patients being treated with methotrexate (25mg or less per week). About your medicine Methotrexate is
More informationVandetanib. ICD-10 codes Codes with a pre-fix C73.
Vandetanib Indication First line treatment of histologically confirmed, unresectable, locally advanced or metastatic medullary thyroid cancer in patients with progressive and symptomatic disease. ICD-10
More informationBCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine
BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine Protocol Code Tumour Group Contact Physician GIPAVCAP Gastrointestinal GI Systemic
More informationPRODUCT MONOGRAPH TARCEVA. erlotinib hydrochloride tablets. erlotinib 25, 100, 150 mg
PRODUCT MONOGRAPH Pr TARCEVA erlotinib hydrochloride tablets erlotinib 25, 100, 150 mg Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Protein Kinase Inhibitor (L01XE03) Hoffmann-La Roche
More informationTechnology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta257
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the firstline treatment of metastatic hormone- receptor-positive e breast cancer that overexpresses HER2 Technology appraisal guidance
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More information